Tpi 1020, a novel inhaled anti-inflammatory drug, has a different pharmacokinetic profile and lower effect on urinary free cortisol as compared to budesonide
R. Pageau, A. Brasey, M. Fortin, R. Seguin, A. Guimond, L. P. Boulet, F. Maltais, J. Milot, P. M. Renzi, N. Ferrari (Montreal, Quebec, Canada)
Source: Annual Congress 2009 - Translational research/biomarkers
Session: Translational research/biomarkers
Session type: E-Communication Session
Number: 2931
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Pageau, A. Brasey, M. Fortin, R. Seguin, A. Guimond, L. P. Boulet, F. Maltais, J. Milot, P. M. Renzi, N. Ferrari (Montreal, Quebec, Canada). Tpi 1020, a novel inhaled anti-inflammatory drug, has a different pharmacokinetic profile and lower effect on urinary free cortisol as compared to budesonide. Eur Respir J 2009; 34: Suppl. 53, 2931
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma Source: Eur Respir J 2006; 28: 1042-1050 Year: 2006
Anti-inflammatory effect of montelukast (ML) and inhaled steroids (ICS) on clinical parameters and serum levels of NO in asthmatic children Source: Eur Respir J 2003; 22: Suppl. 45, 132s Year: 2003
Efficacy of low dose theophylline in patient with bronchial asthma - anti-inflammatory effect Source: Eur Respir J 2003; 22: Suppl. 45, 102s Year: 2003
Repeated inhalation of the new topical steroid ciclesonide does not lead to suppression of endogenous cortisol release in healthy subjects Source: Eur Respir J 2001; 18: Suppl. 33, 95s Year: 2001
Low systemic exposure of NVA237, an inhaled once-daily anticholinergic bronchodilator, in healthy humans Source: Eur Respir J 2006; 28: Suppl. 50, 661s Year: 2006
Vilanterol, a novel inhaled long-acting β2 adrenoceptor agonist (LABA), demonstrates extensive first pass clearance to metabolites with negligible pharmacological activity in man Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Effect of a novel inhaled glucocorticoid, ciclesonide, on an allergen-induced asthmatic response in rats and its prolonged anti-inflammatory activity in vitro Source: Eur Respir J 2002; 20: Suppl. 38, 91s Year: 2002
The combination of budesonide and formoterol exerts more rapid and enhanced anti-inflammatory effects than either drug alone in rat lungs in vivo Source: Eur Respir J 2004; 24: Suppl. 48, 344s Year: 2004
Effects of low dose inhaled theophylline (ADC4022) co-administered with budesonide on inflammatory markers, lung function, and quality of life in COPD patients Source: Annual Congress 2009 - New drugs for airways disease Year: 2009
The influence of β2 adrenoceptor polymorphisms on the response to formoterol, montelukast or higher dose budesonide in patients with uncontrolled asthma despite low dose budesonide Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids Year: 2004
Fluticasone furoate (FF), a once-daily inhaled corticosteroid (ICS), demonstrates dose-response efficacy in patients symptomatic on non-steroidal asthma therapy Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
Fluticasone propionate/formoterol fumarate combination therapy has an efficacy and safety profile similar to that of its individual components administered concurrently in the treatment of asthma Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010
The safety, tolerability, pharmacodynamics and pharmacokinetics of inhaled fluticasone furoate (FF) and vilanterol (VI) are unaffected by administration in combination Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Low systemic exposure to aclidinium bromide, a novel long-acting anticholinergic, after multiple doses Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008
Pharmacokinetic factors affecting airway selectivity of inhaled steroids – role of prodrug conversion and absorption Source: Eur Respir J 2004; 24: Suppl. 48, 347s Year: 2004
Comparison of the pharmacokinetic, pharmacodynamic, and safety profiles of three different formulations of intravenous epoprostenol sodium Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012
The effect of ketoconazole on the pharmacokinetics (PK) and pharmacodynamics (PD) of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in healthy subjects Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD7594 after single and multiple ascending inhaled doses in healthy Japanese males Source: International Congress 2017 – COPD management Year: 2017
A phase 1 multiple dose safety and pharmacokinetics study of AIR645, an inhaled IL-4rα 2-MOE GAPMER oligonucleotide Source: Annual Congress 2009 - New drugs for airways disease Year: 2009
Effects of long acting β2-agonist, sustained-release theophylline and their combination on exercise parameters in asthmatic patients Source: Eur Respir J 2002; 20: Suppl. 38, 287s Year: 2002